HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients. Ellen Kitchell, M.D.
|
|
- Betty Riley
- 5 years ago
- Views:
Transcription
1 HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D.
2 A Smorgasbord of Possibilities
3 Picking Out A Delicious Meal For Your Patient There are many fantastic options currently for patients with HIV that have few side effects and with minimal pill burden Certain factors influence your decisions in choosing a regimen for an individual patient (no one size fits all regimen) You are somewhat like a waiter to suggest a regimen that your patient will like to take
4 The Art of HAART
5 Goals of Therapy To come up with a regimen that a patient can take lifelong Durably suppress HIV viral load to <48 copies/ml Provide regimen that is compatible with patient s lifestyle, in order to ensure maximal adherence Minimize toxicity
6 A very good place to start Department of Health and Human Services Guidelines International AIDS Society-USA (IAS-USA) al-treatment-adult-hiv-infection-0
7 STARTING HAART: OPTIMAL TIMING
8 A Long Story Short All patients regardless of CD4 count should be offered antiretroviral therapy Very few exceptions 2 rationales: Individual medical benefit Prevention of transmission
9 START Trial Patients with CD4 count >500 cells/ul Randomized to either immediate initiation of therapy versus deferred until CD4 <350 cells/ul or clinician s judgment Evaluation of mortality, non-aids events, hospitalizations, bone mineral density, etc.
10 START 57% reduced risk of serious events or death with immediate ART 72% reduced risk of serious AIDS events with immediate ART AIDS-related events: any AIDS-defining illness as defined by CDC Serious non-aids defining events: CV disease, ESRD, death from liver disease, cancer
11 START Most of these endpoints occurred in pts with CD4+ cell counts > 500 cells/mm 3 Reduced risk of cancers, particularly in rates of Kaposi sarcoma and lymphoma No difference in rate of cardiovascular events between the arms, although study had to be stopped early INSIGHT START Group. N Engl J Med. 2015;373:
12 HPTN 052: HIV Transmission Reduced by 96% in Serodiscordant Couples Linked Transmissions: 28 Delayed Arm: 27 Immediate Arm: 1 Single transmission in patient in immediate HAART arm believed to have occurred close to time therapy began and prior to suppression of genital tract HIV P <.001 Cohen MS, et al. N Engl J Med. 2011;365:
13 Update of HPTN 052 After results returned, ART offered to all pts in study No linked HIV transmissions observed when index participant stably suppressed on ART Risk reduction attributed to early ART was 93% HIV Infections Early Delayed All Linked 3 43 NEJM 2016; 375(9):
14 PARTNER Study 1166 serodifferent couples 40% MSM Inclusion criteria of having sexual contact without condoms at least some of the time HIV+ partner on ARVs, VL <200 copies/ml No documented cases of within-couple HIV transmission Rodger A. JAMA 2016; 316(2):
15 PARTNER MSM serodifferent couples from 14 European countries HIV+ partner was on suppressive ART Couples reported >77,000 episodes of condomless anal sex No transmission events during study period of 7 years Rodger A et al. Risk of HIV transmission through condomless sex in gay couples with suppressive ART: the PARTNER2 study expanded results in gay men. 22nd International AIDS Conference, Amsterdam, abstract WEAX0104LB, 2018.
16 Potential Benefits of Antiretroviral Therapy Initiation at High CD4 Counts Benefits: Prevention of AIDS events, even at high CD4 count Possible prevention of cancer, heart disease Possible prevention of neurocognitive decline Prevention of transmission
17 Potential Risks of Antiretroviral Therapy Initiation at High CD4 Counts Toxicities (including long-term toxicities, which may not be known) Development of resistance Adherence concerns Cost, in resource-limited settings
18 Guidelines for Timing of Antiretroviral Therapy 2018: DHHS and IAS-USA Antiretroviral therapy (ART) is recommended for all HIV-infected individuals, regardless of CD4 T lymphocyte cell count, to reduce the morbidity and mortality associated with HIV infection (AI). ART is also recommended for HIV-infected individuals to prevent HIV transmission (AI).
19 Guidelines for Antiretroviral Initiation: World Health Organization ART should be initiated in all adults living with HIV, regardless of WHO clinical stage and at any CD4 cell count
20 HAART IN THE TRENCHES: INITIATING IN THE SETTING OF OPPORTUNISTIC INFECTION
21 Previous Thoughts About ARV Initiation in Patients with Opportunistic Infections Concern for immune reconstitution syndrome (IRIS), which can cause clinical worsening when the patient s immune system starts to wake up Previously delayed ARVs for weeks to months to avoid this complication
22 ACTG 5164: Immediate versus Deferred Antiretroviral Therapy in the Setting of Opportunistic Infection Randomized patients with OIs to starting ART within 14 days versus deferring on average for 45 days AIDS progression/death in 14% of early HAART versus 24% in deferred arm (not statistically significant) However, fewer AIDS progression/deaths and longer time to AIDS progression/death
23 Caveats to ACTG 5164 Most patients included in study had Pneumocystis pneumonia, which has low risk of IRIS Other opportunistic infections more likely to cause life-threatening IRIS
24 HAART-Immediate Opportunistic Infections Symptomatic HIV infection Cryptosporidium/Microsporidium Kaposi s Sarcoma Lymphoma (especially PCNSL) PML HIV dementia
25 What are Opportunistic Infections with High Risk of IRIS to delay therapy? Cryptococcal meningitis Increased mortality with early ARV initiation in RCT comparing starting w/in 1-2 weeks versus waiting 5 weeks Recommended to delay 2-10 weeks Worse outcome if initial CSF WBC was <5, increased intracranial pressure
26 Other Opportunistic Infections Tuberculosis Recommendations to start therapy depend on baseline CD4 If <50 cells: start therapy w/in 2 weeks If >50, start w/in 8 weeks Caution regarding TB meningitis
27 CMV retinitis No specific recommendations, consider delay 1-2 weeks Toxoplasmosis No specific recommendations but I typically wait 2-3 weeks
28 WHAT TO START
29
30 Considering HAART Options 1. Will the regimen be expected to work against the patient s virus? Resistance testing results 2. Consider comorbidities, especially hepatitis B and C status 3. Baseline labs, including renal, hepatic function 4. Drug interaction issues and potential drug interactions 5. Potential side effects of the regimen: how will this affect the patient and adherence to medications 6. Lifestyle issues: ability to adhere to regimens, pill burden 7. For women, plans for pregnancy 8. Cost/insurance issues
31 Recommendations from Expert Panels DHHS, IAS, WHO Have preferred regimens selected on efficacy, tolerability Sometimes the preferred regimen for your patient is not one of these options
32 Recommended Regimens: DHHS Guidelines nucleos(t)ide reverse transcriptase inhibitors (NRTIs) + 3 rd active drug Integrase inhibitor (INSTI) = main dish Lamivudine OR emtricitabine = the fries Abacavir OR tenofovir = the drink? Have tried 2 drugs and 4+ medications, nothing seems to work as well for now, 3 is the magic number!
33 DHHS Guidelines: Preferred Raltegravir (ISENTRESS) With emtricitabine/tenofovir DF (TRUVADA) With emtricitabine/taf (DESCOVY)
34 Preferred Regimens: DHHS Elvitegravir With emtricitabine/tenofovir DF (co-formulated as STRIBILD) With emtricitabine /tenofovir AF (coformulated as GENVOYA)
35 Preferred Regimens: DHHS Dolutegravir (TIVICAY) With abacavir/lamivudine (EPZICOM or TRIUMEQ) With tenofovir DF/emtricitabine (TRUVADA) With tenofovir AF/emtricitabine (DESCOVY)
36 DHHS Guidelines: Preferred (New Update as of 3/2018) BIKTARVY: Bictegravir + emtricitabine + tenofovir alafenamide
37 Alternative Regimens for DHHS Considered effective and tolerable, but with potential disadvantages, limitations for use in certain populations or less supporting data from clinical trials Darunavir/cobi or darunavir/ritonavir + tenofovir/ftc or abacavir/lamivudine Boosted atazanavir + tenofovir DF or AF Efavirenz/emtricitabine/tenofovir DF or AF
38 Other Regimens If HIV RNA <100,000 copies/ml Boosted atazanavir + abacavir/lamivudine Efavirenz + abacavir/lamivudine Rilpivirine/tenofovir/emtricitabine (also need CD4 >200 cells/ul) Raltegravir + abacavir/lamivudine
39 IAS Recommendations 2018 Bictegravir/tenofovir alafenamide/emtricitabine Dolutegravir/abacavir/lamivudine Dolutegravir/tenofovir alafenamide/emtricitabine
40 WHO Recommendations Efavirenz + tenofovir + lamivudine (or emtricitabine) Alternative: dolutegravir + tenofovir + lamivudine
41 Comparison of Current International Guidelines for Treatment-Naive Pts Regimen DHHS IAS-USA WHO DTG/3TC/ABC* DTG + FTC/TDF or TAF EVG/COBI/FTC/TDF EVG/COBI/FTC/TAF RAL + FTC/TDF or TAF ATV/RTV + FTC/TDF DRV/RTV + FTC/TDF EFV/FTC/TDF RPV/FTC/TDF Recommended Alternative Not included *Only if HLA-B*5701 negative. Only if CrCl 70 ml/min. Only if CrCl 30 ml/min. Only if baseline HIV-1 RNA < 100,000 copies/ml and CD4+ cell count > 200 cells/mm 3.
42 THE MAIN DISH
43 Use of Efavirenz in Naïve Patients (SUSTIVA/ATRIPLA) Cheap(er) and a lot of side effects!
44 Efavirenz Is Efficaceous Up until recently, efavirenz was non-inferior or superior to other ARVs at suppressing HIV, regardless of baseline viral load or CD4 Key studies comparing efavirenz to other options: ACTG 5142 efavirenz superior to lopinavir/ritonavir (KALETRA) ACTG 5202: non-inferior to atazanavir/ritonavir ECHO/THRIVE: non-inferior to rilpivirine GS-US : non-inferior to elvitegravir
45 More Recent Efficacy Trials In studies of newer integrase-inhibitor regimens, some regimens have demonstrated superiority to efavirenz Primarily based on more discontinuations due to adverse effects in efavirenz arm
46 Adverse Effects of Efavirenz/Atripla Neuropsychiatric side effects are common: Strange/vivid dreams in ~50% Dizziness/feeling drunk Depression, unstable mania Increased suicidality noted Potential teratogen Some drug interactions (substrate of CYP3A4 and inducer of 3A4/2D6) Usually take at bedtime on empty stomach Low genetic barrier to resistance Includes tenofovir DF, no plans to co-formulate with other options
47 Rilpivirine: Alternative Therapy Very few side effects Not as potent Not for patients with heartburn
48 Alternative Therapy: Rilpivirine NNRTI medication set to compete with Atripla Co-formulated with emtricitabine/tenofovir DF (Complera) and FTC/TAF (Odefsey) Very well tolerated compared to Atripla However, more virologic failures, particularly in patients with low CD4 and high viral load (>100,000 copies/ml) ECHO/THRIVE. Lancet 2011; 378(9787):
49 Rilpivirine Usage Only approved for relatively well, adherent patients CD4 >200 cells/ul Viral load <100,000 copies/ml PPI lowers absorption Need to eat a high fat, large meal for absorption
50 Protease Inhibitor Based Regimens Durable, tough even in non-adherent patients Drug interactions Side effects
51 Protease Inhibitors Very potent class of medications Very low rates of baseline resistance Durable at suppressing virus High genetic barrier to resistance If patients fail a PI based regimen, rarely develop mutations, and if so, PI mutations are very rare (not true of integrase or NNRTI based regimens) Forgiving of non-adherence
52 Protease Inhibitors Recommended by many (including myself) to use in situation where genotype is not available yet
53 Adverse Effects of the Protease Inhibitor Class Gastrointestinal side effects (nausea/vomiting/diarrhea) Inhibit cytochrome P450 enzyme system Need to take with food Metabolic abnormalities Dyslipidemia Insulin resistance Lipodystrophy, weight gain Older Pis implicated in stroke, MI
54 Pill Burden with Protease Inhibitors Previously had greater pill burden with protease inhibitors which limited adherence Now with multiple co-formulated options with modern PIs: Evotaz (atazanavir/cobicistat) Prezcobix (darunavir/cobicistat) Symtuza (darunavir/cobicistat/tenofovir alafenamide/emtricitabine)
55 Efficacy Trials for Atazanavir (Reyataz) ACTG 5202 showed similar efficacy between efavirenz + atazanavir GS showed similar efficacy between elvitegravir + atazanavir ACTG 5257 showed similar virologic efficacy between atazanavir, darunavir and raltegravir However, more treatment discontinuations in atazanavir group
56 Unique Adverse Effects to Atazanavir Indirect hyperbilirubinemia Functional Gilbert s syndrome Expected and harmless to patient except for cosmetic appearance Scleral icterus, jaundice Some patients do not like the appearance Is NOT supposed to cause AST/ALT elevation Need for acidic gastric ph for absorption Nephrolithiasis (rare)
57 Efficacy Trials for Darunavir in Naïve Patients ARTEMIS showed superior efficacy to old PI, Kaletra ACTG 5257 showed similar virologic efficacy to raltegravir FLAMINGO study showed darunavir had lower rate of virologic suppression than dolutegravir Driven by drug discontinuation in darunavir group
58 Unique Adverse Effects to Darunavir Sulfonamide moiety Use in caution with patients with severe sulfa allergy; however most patients with h/o sulfa allergy tolerate darunavir well
59 Cobicistat Can be used as a booster for increasing drug levels of protease inhibitors and elvitegravir Co-formulated with multiple regimens Not recommended as preferred in DHHS because not as much clinical trial data
60 Protease Inhibitors in the Guidelines No longer recommended as first line in the DHHS and IAS guidelines Side effect burden Issues with drug interactions Is recommended for patients with concerns over adherence given their potency
61 Integrase-Inhibitor Based Regimens
62 Patients With HIV-1 RNA < 50 copies/ml (%) STARTMRK: Virologic and Immunologic Efficacy at Wk % 82% 81% 79% Study Week RAL EFV Significantly shorter time to virologic response with RAL vs EFV (P =.001)
63 Other Efficacy Studies for Raltegravir ACTG 5257 compared atazanavir, darunavir and raltegravir in combination with tenofovir/emtricitabine Similar virologic efficacy in all arms Fewer discontinuations in darunavir and raltegravir arms Ann Intern Med Oct 7; 161(7):
64 ACTG 5257 Virologic failure with drug resistance occurred infrequently More common in patients assigned to raltegravir arm Integrase inhibitor mutations found in all patients who developed virologic failure with drug resistance
65 Efficacy in Clinical Trials of Raltegravir SPRING-2 compared dolutegravir versus raltegravir in naïve patients Used background of abacavir/lamivudine or tenofovir/emtricitabine No difference in virologic response Lancet Infectious Diseases 13(11): P
66 Once-Daily Raltegravir: ONCEMRK Use of raltegravir 2 tablets of 600 mg dosage once daily compared with 400 mg twice daily In combination with emtricitabine/tenofovir DF Similar virologic suppression rates Similar side effect profile Cahn P. Lancet HIV. 2017
67 Adverse Effects of Raltegravir Very well tolerated Rarely causes CPK elevations, rhabdomyolysis, myositis Rare rashes Minimal drug interactions great for psych patients and herbal medication takers No food requirement but need to avoid divalent cations
68 Raltegravir Versus Other Options Benefits of using raltegravir Considered least metabolically toxic, both in terms of lipodystrophy and effect on triglycerides Lack of drug interactions Minimal side effects Quick virologic suppression and immunologic recovery Concerns about raltegravir Lower genetic barrier to resistance than PIs and second generation integrase inhibitors Greater number of pills
69 Why would you use elvitegravir (STRIBILD or GENVOYA)? Well-tolerated, low pill burden Renal issues Drug interactions Lower genetic barrier to resistance
70 Elvitegravir Elvitegravir/cobicistat was non-inferior to efavirenz containing regimen Did see resistance mutations developing in patients failing therapy in both arms of the study Journal of Acquired Immune Deficiency Syndromes. 2014;65(3):e
71 Safety of Elvitegravir/Cobicistat vs Efavirenz Elvitegravir very well-tolerated, main side effect was nausea, headaches Significantly greater increase in median serum creatinine from EVG/COBI group Thought to be related to cobicistat inhibition of creatinine secretion in distal tubule In Stribild (with tenofovir DF), limited use only in patients with creatinine clearance of >70 ml/min Genvoya (with tenofovir AF), can use down to CrCl 30 ml/min JAIDS 2013; 63(1):
72 Elvitegravir versus Atazanavir Elvitegravir/cobicistat non-inferior to atazanavir/ritonavir regimen In patients with confirmed virologic failure, resistance detected in 5/12 patients in elvitegravir arm; no resistance in atazanavir arm Not as tough as the PIs!
73 Pros and Cons of Elvitegravir Pros Low side effect profile Highly effective at viral suppression Low pill burden Cons Drug interactions Food requirements Expense Monitoring renal function Genetic barrier to resistance not as high as other meds
74 Why use dolutegravir (TIVICAY/TRIUMEQ)? Potent, low side effect burden Seems to have high genetic barrier to resistance Recent concerns about teratogenicity
75 Dolutegravir + Abacavir/Lamivudine versus Efavirenz/tenofovir/emtricitabine (SINGLE)
76 Dolutegravir Versus Efavirenz Dolutegravir was statistically superior at suppressing viral load at 48 and 96 weeks No integrase or NRTI mutations detected in patients on dolutegravir Dolutegravir had lower rate of CNS side effects and rash Fewer discontinuations due to AEs in dolutegravir group (10% in Atripla arm)
77 SPRING-2: Dolutegravir Noninferior to Raltegravir at 96 Wks (81% vs. 76%)
78 FLAMINGO Trial Open-label trial comparing dolutegravir to darunavir/ritonavir Could use abacavir/lamivudine or tenofovir/emtricitabine
79 FLAMINGO Results: Dolutegravir Superior to Darunavir in HIV <50 copies/ml (90% vs. 83%)
80 FLAMINGO Results Treatment success driven by higher discontinuation rates for darunavir patients (4% versus 2% in dolutegravir group) 2 patients in each group had virologic failure No treatment-emergent mutations detected Suggests that dolutegravir has high genetic barrier to resistance
81 Dolutegravir Insomnia and headache in 2% of patients Post-marketing notes concern for mood changes in some patients Decreased tubular secretion of creatinine, does not affect renal function Very few drug interactions (but still a few!) E.g. metformin, seizure medications, St. John s wort
82 Dolutegravir and Concerns About Teratogenicity Observational study of birth outcomes in pregnant women in Botswana Found 4/426 infants born with neural tube defects in women who were taking dolutegravir at the time of conception Also included 116 women who started on dolutegravir in 1 st trimester, no birth defects noted in this group No previous birth defects noted, including in United States Unclear whether dolutegravir is the only integrase inhibitor that can potentially do this Still awaiting additional data from this study
83 Dolutegravir Current Recommendations Per DHHS Recommend avoiding dolutegravir in women who: Desire pregnancy Not using effective contraception First trimester of pregnancy or possible pregnancy Check pregnancy testing prior to starting
84 Why use bictegravir (Biktarvy)? Potent, low side effect burden Seems to have high genetic barrier to resistance Newest antiretroviral
85 Bictegravir GS-US randomized patients to receive bictegravir/taf/ftc or dolutegravir/taf/ftc At week 48, 89% of patients in bictegravir arm and 93% of patients in dolutegravir arm had VL <50 GS-US randomized patients to Biktarvy versus Triumeq 92% of patients in bictegravir arm and 93% of patients in Triumeq were virally suppressed
86 Side Effects of Bictegravir (5%, mild) Nausea Diarrhea Headache Dizziness Insomnia
87 Regimen Advantages Disadvantages Efavirenz Rilpivirine Proteaseinhibitor based Raltegravir Elvitegravir Dolutegravir Bictegravir Cost Single-tablet regimen Long-term data available Single-tablet regimen Well-tolerated Most forgiving for non-adherent patients Safe to use in patients without genotype information Minimal adverse effects Very few drug-drug interactions Single tablet regimen Well-tolerated Single tablet regimen Few side effects High genetic barrier to resistance Single tablet regimen Low side effect profile High genetic barrier to resistance CNS side effects Teratogenicity Low genetic barrier to resistance Low genetic barrier to resistance Higher virologic failures in high viral loads Need for acid for absorption Metabolic side effects Drug interactions For atazanavir, jaundice and need for acid for absorption Higher pill burden Lower genetic barrier to resistance than protease inhibitors Renal effects Drug interactions Lower genetic barrier to resistance than protease inhibitors Mild renal effects Rare mood side effects Teratogenicity? New medication Few drug interactions
88 SIDE DISHES
89 The Fries of the Regimen: Lamivudine or Emtricitabine One of the earliest developed antiretrovirals Very safe, well-tolerated Emtricitabine very similar structure Use interchangeably Very similar resistance pattern (no reason to use both medications) Used in almost all regimens for HIV
90 Choosing Between the NRTIs: Abacavir versus Tenofovir
91 Abacavir Went Away then Returned to DHHS Previously had fallen off due to concerns about: Efficacy in comparison with tenofovir Possible cardiovascular toxicity Hypersensitivity reaction No activity against hepatitis B infection
92 ACTG 5202: Abacavir vs Tenofovir Study discontinued early In patients treated with atazanavir and efavirenz More virologic failure observed with abacavir in patients with HIV RNA >100,000 copies/ml versus in tenofovir.
93 HIV-1 RNA HEAT: Abacavir Noninferior to Tenofovir, even at high HIV viral loads ABC/3TC + LPV/RTV* (n = 343) TDF/FTC + LPV/RTV* (n = 345) < 50 copies/ml (%) [1] M = F MD = F VF (%) [2] ,000 copies/ml 250,000 - < 500,000 copies/ml 100,000 - < 250,000 copies/ml < 100,000 copies/ml ABC/3TC (n = 49) TDF/FTC (n = 48) Smith KY, Patel P, Fine D, et al; HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):
94 Dolutegravir Trials (SINGLE, FLAMINGO) No differences between abacavir or tenofovir in virologic efficacy, even at high viral loads (>100k)
95 Abacavir in DHHS Guidelines Recommended in patients taking dolutegravir (extensively tested) Use in efavirenz or atazanavir based regimens only if viral load is <100k ***Considered as alternative *** Probably ok with darunavir based regimens (not tested) Not much data with rilpivirine or raltegravir
96 Abacavir and Cardiovascular Risk D:A:D cohort study has thousands of patients on multiple regimens Found that patients recently started (within 6 months) associated with increased risk of MI, particularly in patients with CV risk factors
97 Summary of Clinical Trial and Cohort Analyses of ABC Use and CVD Risk Study Design CV Events Effect of ABC? D:A:D [1] (N = 33347) Observational cohort Prospective, predefined Yes FHDH [2] (N = 1173) Case control study MI retrospectively validated SMART [3] (N = 2752) RCT, observational analyses Prospective, predefined Yes 1st yr of exposure STEAL [4] (N = 357) RCT Prospective Yes GSK analysis [5] (N = 14174) ALLRT ACTG A5001 [6] (N = 3205) 54 RCTs Retrospective database search No 5 RCTs All or majority of pts antiretroviral-experienced at ABC initiation All or majority of pts antiretroviral-naive at ABC initiation Retrospective by 2 independent reviewers Yes No 1. Lundgren JD, et al. CROI Abstract 44LB. 2. Lang S, et al. CROI Abstract 43LB. 3. SMART. AIDS. 2008;22:F17-F Carr A, et al. CROI Abstract Cutrell A, et al. IAC Abstract WEAB Benson C, et al. CROI Abstract 721. Reiss P. CROI Abstract 152.
98 Cardiovascular Risk of Abacavir Bedimo et. al (CID (1): 84-91) used Veterans Association data to calculate risk of MI and stroke in patients on abacavir and other combinations Controlled for chronic kidney disease, smoking, lipids etc. Observed NO association between abacavir use and MI or CVA once CKD accounted for
99 Cardiovascular Risk and Abacavir Meta-analysis of randomized, controlled treatment trials and manufacturer data found no evidence that abacavir-containing regimens carry greater risk of MI Cruciani M. AIDS 2011; 25(6):
100 DHHS and IAS Guidelines No consensus has been reached on the association between abacavir use and MI risk or the mechanism for such an association. Abacavir should be used with caution or avoided in patients with known high cardiovascular risk
101 Concerns About Tenofovir
102 Spine BMD Percent Change From Wk 0 Spine BMD Percent Change From Wk 0 ACTG 5224s: Change in Bone Mineral Density Substudy of ACTG 5202 Tenofovir versus abacavir and efavirenz vs atazanavir/ritonavir Primary endpoint Changes in bone mineral density by DXA TDF/FTC ABC/3TC 192 At week 96, significantly greater losses in BMD with Tenofovir vs abacavir in both hip and spine Atazanavir/ritonavir vs efavirenz in spine P =.035* EFV ATV/RTV McComsey GA, et al. J Infect Dis. 2011;203:
103 Tenofovir: Concerns for Renal Toxicity Fanconi s syndrome known potential toxicity of tenofovir Multiple case studies and clinical experience of proximal tubular dysfunction and impaired GFR; several observational cohort studies show rates of renal failure with tenofovir use Meta-analysis showed significantly greater decrease of ml/min and increased risk of acute renal failure (0.7%) in patients receiving tenofovir as compared to other regimens Cooper R. CID 2010:
104 Tenofovir alafenamide (TAF) TAF (GS-7340), prodrug of tenofovir with lower tenofovir plasma concentrations, increased delivery to hepatocytes, lymphoid cells Gut TFV TDF TAF Plasma TDF/TFV TAF Lymphoid Cells TAF Cathepsin A TFV TFV-MP TFV-DP
105 Use of Tenofovir Alafenamide vs TDF in Treatment-Naive Pts Studies 104/111 Compared elvitegravir/cobicistat and tenofovir alefenamide versus disproxil Similar virologic suppression Smaller egfr decline with TAF (but decline noted) Decreased rates of bone loss with TAF Higher lipid levels with TAF due to absence of TDF lipid lowering effect 1. Sax PE, et al. Lancet. 2015;385: Wohl D, et al. J Acquir Immune Defic Syndr. 2016;72:58-64.
106 Tenofovir versus Abacavir Regimen Advantages Disadvantages Abacavir Similar efficacy to tenofovir in HEAT and dolutegravir trials Hypersensitivity can be safely avoided with HLA-B*5701 assay Potential for hypersensitivity reaction Inferior response high viral load in ACTG 5202 Association with risk of myocardial infarction in some studies Tenofovir DF Tenofovir AF High level of efficacy in clinical trials Active against hepatitis B Comparable efficacy to tenofovir DF in clinical trials Less effect on bone and renal Active against hepatitis B Can use in patients with CKD to GFR >30 ml/min Caution in pts with renal insufficiency Long-term nephrotoxicity and tubular toxicity not fully understood Should not be coadministered with other nephrotoxic drugs Bone toxicity Does have some effects on bone and kidney Higher cholesterol levels than TDF
107 Really Alternative Regimens if Cannot Use Tenofovir or Abacavir Darunavir/ritonavir plus raltegravir (BID) if HIV RNA <100,000 copies/ml and CD4 >200 cells/mm 3 (NEAT) Lopinavir/ritonavir + lamivudine (GARDEL) Raffi F, et al. Lancet. 2014;384: Cahn P, et al. Lancet Infect Dis. 2014;14:
108 Other Regimens for Naïve Patients (Not in the Guidelines) ANDES: Small study comparing darunavir/lamivudine and darunavir/lamivudine/tenofovir DF showed similar virologic suppression ATLAS: atazanavir/lamivudine open label trial Cahn P et al. Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study. 9th International AIDS Society Conference on HIV Science, Paris, abstract MOAB0106LB, 2017.
109 Other Regimens For Naïve Patients (Not in the Guidelines Yet) Dolutegravir monotherapy NOT recommended PADDLE, ACTG A5353 trial: dolutegravir + lamivudine open label looked good but small, not randomized GEMINI-1 and 2: compared dolutegravir + lamivudine to dolutegravir/lamivudine/tdf in treatment naïve patients Similar virologic efficacy, no development of resistance (capped at VL <500k) Cahn P. Program and abstracts of the 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands. Abstract TUAB0106LB.
110 New Antiretrovirals Doravirine, novel NNRTI Comparison trials against efavirenz/emtricitabine/tenofovir and darunavir/ritonavir/tenofovir/emtricitabine Just released coformulated doravirine/lamivudine/tenofovir DF (DELSTRIGO) PIFELTRO = doravirine alone Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211-e220.
111 A Little Farther on the Horizon Cabotegravir, novel integrase inhibitor Trial of oral medication Injectable formulation In combination with oral or IM rilpivirine
Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationTUESDAY AM HIV DISCUSSION SERIES. 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D.
TUESDAY AM HIV DISCUSSION SERIES 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D. HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. The Art of HAART
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More information1/13/16. Updated April 2015
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationStribild, a Single Tablet Regimen for the Treatment of HIV Disease
Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationHIV Treatment Update. Objectives. Epidemiology 12/22/2015
HIV Treatment Update Monique Calil, Pharm.D. PGY-1 Resident Broward Health Medical Center Objectives Review antiretroviral therapy (ART) medications used for the treatment of HIV, including new combination
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationExploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationEviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD
Eviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD Population: 8,000,000 Ethnic groups: 75% Jewish 20% Arabs 5% Others HCS PPC 3.5/1000 NPC
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation November
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationReaching HIV-1 Treatment Decisions Without a Patient s Medical Records
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/reaching-hiv-1-treatment-decisions-withoutpatients-medical-records/10466/
More informationDisclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:
Disclosures Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 8, 2017 Research grant support from Gilead Sciences for ongoing work
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationA Changing Landscape: New and Pipeline HIV Therapies
A Changing Landscape: New and Pipeline HIV Therapies Sarah Turley, PharmD, BCPS PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health System Financial Disclosure I have no relevant
More informationClass Review: HIV Antiretroviral Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Education Initiative THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE Speaker: Antonia Urbina, MD 2/1/2017 The Role of the Primary Care Clinician in HIV Care [video transcript]
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More information